Reviewing the FDA Approval and Phase III Clinical Results of Itvisma (onasemnogene abeparvovec-brve) in Spinal Muscular Atrophy from Novartis

Scheduled for:Dec 30, 2026 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A neurologist or neuromuscular disease specialist with deep expertise in spinal muscular atrophy, gene therapy, and clinical trial research in inherited neuromuscular disorders. The expert should have experience managing pediatric and adult SMA patients and be familiar with SMN-targeted therapies, including gene replacement, antisense oligonucleotides, and small-molecule splicing modifiers.

Interview Goal

The interview aims to examine the FDA approval of Itvisma (onasemnogene abeparvovec-brve), the first and only gene replacement therapy approved for children two years and older, adolescents, and adults with spinal muscular atrophy (SMA). The discussion will focus on the Phase III STEER and STRENGTH clinical trial results, the clinical impact of one-time SMN1 gene replacement, long-term motor function stabilization, safety outcomes, and the implications of expanding gene therapy access across all age groups living with SMA.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.